Comparison of 1st and 2nd Generation GcMAF

GcMAF (Gc Protein derived Macrophage Activating Factor)

Comparison of 1st and 2nd Generation GcMAF
For the treatment for cancer, HIV and immune system diseases.

Comparison of 1st and 2nd Generation GcMAF

First Generation GcMAF vs Saisei Mirai Second Generation GcMAF concentration

First Generation GcMAF

Dr Nobuto Yamamoto
  • Developed by Dr Yamamoto in 1991
  • Low concentration (100 ng/0.25 ml, 1 dose)
  • Low stability at room temperature and when refrigerated
  • Gc protein isolated from serum using 25-(OH) Vitamin D3 Affinity Column, making the GcMAF unstable
  • Sterilized using 0.22 micron sterile filtration system
  • Tokushima University conducts experiments with 1st Generation and 2nd Generation GcMAF

Goleic GcMAF, GcMAF with oleic acid, is simply first generation GcMAF with some added components but still having the low concentration of the original first generation GcMAF developed over 20 years ago. Due to limited testing and clinical use, the efficacy of Goleic GcMAF is unknown.

Second Generation GcMAF

Dr Hitoshi Hori, University of Tokushima
Dr Yoshihiro Uto, University of Tokushima
Dr Kentaro Kubo, Saisei Mirai
  • 2nd Generation High Dose GcMAF Developed by the University of Tokushima and Saisei Mirai in 2011
  • New patented production process
  • High concentration (1500 ng/0.5 ml, 1 dose)
  • Very high macrophage activating activity
  • Much higher stability even at room temperature *
  • Demonstrated in vitro to increase the rate of maturation of Dendritic Cells (DCs).
  • Sterilized using 0.22 micron sterile filtration system

* Second Generation GcMAF is best stored refrigerated and will stay fully active for over 1 year. Stability tests indicate that 2nd Generation GcMAF is very temperature stable and retains maximum activity even after 4 weeks at room temperature and 1 week at 40 °C (104 °F).

1991Dr Yamamoto developed GcMAF
1992Dr Yamamoto visited Dr Hori at Tokushima University
GcMAF research started at Tokushima University
1998Dr Uto joined Dr Hori’s GcMAF research team
2002First research papers published on GcMAF in the journals Biotherapy and Comparative Biochemistry & Physiology
2010Tokushima University began collaborating with Saisei Mirai to develop Second Generation High Dose GcMAF
2011Second Generation GcMAF produced in our Cell Processing Center (CPC) for patients. Start of clinical use.
2013Two research papers published in Anticancer Research by Saisei Mirai & Tokushima University
2013Over 1000 patients treated with Saisei Mirai GcMAF
2014New research paper published in Anticancer Research by Saisei Mirai & Tokushima University

If you wish to purchase GcMAF therapy or make an enquiry, please contact us with details of your disease, current treatment and the quantities of Gc-MAF you require.